Abstract Background: The combination of vascular endothelial growth factor receptor tyrosine kinase inhibitors (VEGFR-TKIs) and programmed cell death protein 1 (PD-1) inhibitors has become a standard first-line treatment for advanced clear cell renal cell carcinoma (ccRCC). However, cardiovascular toxicities associated with this combination require further clinical attention.
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile